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A B S T R A C TObjectives: Morbid obesity represents high costs to health institu-
tions in controlling associated comorbidities. It has been shown that
bariatric surgery resolves or improves comorbidities, thus reducing
resource utilization. This analysis estimated the total costs of treating
morbid obesity and related comorbidities through conventional treat-
ment compared to bariatric surgery under the Mexican public health
system perspective. Methods: An economic evaluation model was
developed by using discrete event simulation. One hundred fifty
patients were created in each arm, with considered comorbidities
allocated randomly. Preoperative comorbidity prevalences and bariatric
surgery’s efficacy for resolving them were obtained from published
literature. Comorbidity treatment costs were obtained from the 2007
Mexican Institute of Social Security diagnosis-related group list and
publications from the National Institute of Public Health. Only 12
patients were operated each month on the surgical arm. Complications
associated with comorbidities were not considered. The considerednt matter Copyright & 2012, International Society
r Inc.
.1016/j.vhri.2012.09.012
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its.jnj.com.
ondence to: Olivo Omar Zanela, Javier Barros Sierratime frame for simulation was 10 years, with a 4.5% annual
discount rate. Results: Return on investment, or cost breakeven point,
for bariatric surgery was obtained after 6.8 years. Total costs for the
surgical group were 52% less than conventional treatment group
costs after 10 years. Bariatric surgery reduced the cost of treating
type 2 diabetes, hypertension, and hypercholesterolemia by 59%, 53%,
and 65%, respectively. Return on investment for bariatric surgery in
patients with type 2 diabetes as the only comorbidity was 4.4 years.
Conclusions: Despite conservative assumptions, investment in baria-
tric surgery is recouped in 6.8 years, generating relevant potential
savings in the treatment of morbidly obese patients. In high-risk
subpopulations, return on investment time is shorter.
Keywords: bariatric surgery, discrete event simulation, economic
evaluation, Mexico, morbid obesity, return on investment.
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The growing prevalence of excess weight (body mass index
[BMI] Z 25 kg/m2) and obesity (BMI Z 30 kg/m2) observed world-
wide in the last 20 years is a major cause of concern for health
systems because of their significant economic and social burden
[1]. Surveys and investigations from various countries have
shown a general upward trend in the prevalence of morbid
obesity (BMI Z 40 kg/m2). In the United States, one in five
obese people is morbidly obese [2]; in Australia, morbid obesity
has increased fourfold in the last 20 years [3]; in Chile, the
National Health Survey showed that the prevalence of morbid
obesity was 1.3% [4]. For Mexico, the prevalence of morbid
obesity was 1.9%, according to the National Health Survey in
2000 [5].
Morbid obesity is associated with higher mortality and lower
quality of life (QOL) than that reported by normal weight patients:
death rates are 2 to 12 times higher [6], and health-related QOL is
poorer, as morbidly obese patients report being worse-off in their
breathing, sleep, mobility, and sexual activity [7]. Obesity-related
comorbidities are highly prevalent among this subpopulation:Buchwald et al. [8] reported that 22.3% had type 2 diabetes (T2D),
41.0% had hypertension, and 35.7% had dyslipidemia.
The growing prevalence of morbid obesity represents a greater
demand of resources on health systems. In the United States,
it was estimated that the direct medical costs of morbidly obese
patients were 60% greater than those incurred by patients with
normal weight [9]. Patients with a BMI of more than 35 kg/m2
represented 37% of the obese population and consumed 61% of the
resources [10], while the annual cost of treating an overweight patient
was less than half of that incurred by a morbidly obese patient [11]. It
was estimated that the costs of obesity corresponded to 4.1% of the
total health care costs in Canada [12], while the medical costs
associated with obesity in the United States were US $147 billion
[13]. For Mexico, there is no published evidence of how much morbid
obesity costs the health system, and such information would be
valuable for treatment and reimbursement decision making.
Because of its favorable results, bariatric surgery has gener-
ated more interest, leading to a significant increase in the
number of procedures performed. It is estimated that 344,221
bariatric surgeries were performed in 2008 [14], with the most
common procedures being laparoscopic adjustable gastricfor Pharmacoeconomics and Outcomes Research (ISPOR).
o conflicts of interest with regard to the content of this article.
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Table 1 – Preoperative comorbidity prevalences.
Comorbidity Preoperative
prevalence
Source
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mentioning sleeve gastrectomy, a new surgical technique that
has been gaining popularity because of its simplicity and good
short- and midterm outcomes [15].
As an alternative to conventional treatment, bariatric surgery
has shown better results in reducing excess weight and improv-
ing QOL. Weight loss with conventional treatment is moderate
and seldom sustained [16]; in contrast, bariatric surgery results in
a 53.82% excess weight loss after 2 years [8], yielding greater
weight loss and improved QOL than conventional treatment [17].
Bariatric surgery reverses, eliminates, or significantly reduces
comorbidities, such as T2D, arterial hypertension (AHT), and
hypercholesterolemia (HCL). It has been shown that bariatric surgery
resolved or improved T2D and AHT in morbidly obese patients in
87% and 79% of the cases, respectively [8,18]. The Swedish Obese
Subjects (SOS) study, an ongoing, nonrandomized, matched, pro-
spective, and controlled trial, with a median follow-up of 14.7 years,
has shown that bariatric surgery is an effective intervention to
achieve sustainedweight loss, while treating and preventing obesity-
related comorbidities; the authors also found that bariatric surgery is
associated with fewer cardiovascular deaths and total first-time
cardiovascular events than conventional treatment [19].
Bariatric surgery is a cost-effective intervention to treat
morbid obesity when compared to nonsurgical treatment, with
incremental cost-effectiveness ratios within acceptable ranges
when evaluated in different settings [20–22]. Cre´mieux et al. [23]
showed that the investment in these surgical procedures is
returned between 2 and 4 years after it was performed, while
Mullen and Marr [24] found that the return on investment (ROI)
point of gastric bypass is 3.5 years.
Economic evaluation of health care interventions is typically
performed by using models based on the behavior of cohorts
of patients (decision trees, Markov models), but they have their
limitations, as they generally assume normally distributed averages
of certain patient characteristics and no correlation between them.
As well, cohort-based models are based on memoryless features and
do not allow for the simultaneous development of multiple events
and/or the transition to multiple health states. Works such as that by
Caro et al. [25] indicate the need to develop models for the economic
evaluation in health care considering the individual behavior of
patients, allowing for patient heterogeneity, multiple resource utili-
zation, and individual outcomes based on individual clinical history.
In models based on discrete event simulation (DES), it is
possible to assign characteristics to patients on an individual
and random basis, so as to establish and quantify the relation-
ship between their baseline characteristics and the events or
interventions they undergo [26]. DES allows to study systems and
processes whose states change over time, to model the natural
clinical course of a disease and its management in terms of the
events that can occur during the process, and to quantify the use
of resources (such as consultations, drugs, and diagnostic tests).
DES also enables resource restriction, such that the actual
conditions of health systems (surgical capacity, waiting lists)
are clearly expressed. As morbid obesity is a chronic condition,
the use of DES could provide a realistic approach to model the
disease, its treatment alternatives, and its consequences.
The objective of this study was to estimate the ROI time, or
cost breakeven point, for bariatric surgery in patients with
morbid obesity with one or more of the three most common
comorbidities, from the perspective of the Mexican public health
system, by means of a DES model.(%)
Type 2 diabetes 22.3 Buchwald et al. [8]
Hypertension 41.0 Buchwald et al. [8]
Hypercholesterolemia 27.9 Buchwald et al. [8]Methods
A model for the economic evaluation of morbid obesity was
developed by using DES because of its advantages in terms ofcontrolling and assessing the history of each patient and esti-
mating the ROI point [27].
To reflect the current local public health care setting, 150
patients were created, to whom comorbidities (T2D, AHT, and
HCL) were assigned randomly, according to the prevalences for
morbidly obese patients reported by Buchwald et al. [8] (Table 1).
It was assumed that all created patients were adult, at least grade
II obese (BMI Z 35 kg/m2), had at least one comorbidity, and had
been previously and unsuccessfully treated with nonsurgical
treatment, as established by European and local guidelines [28,29].
It was assumed that comorbidity prevalences were independent,
as there is no local information on crossed-prevalences for the
targeted population.
In the model, two comparison arms were included: 1) without
surgical intervention (control arm) and 2) with surgical interven-
tion (bariatric surgery arm). Once a patient (and his or her clinical
profile) was created, he or she was cloned so that each arm had
an identical cohort in terms of patients and comorbidities.
Comorbidities in both arms were treated pharmacologically from
the start of the simulation, while their associated complications
were not considered.
Only 12 patients were operated each month on the surgical
arm. This operative restriction is the source of the waiting
list patients face in real conditions; while waiting their turn
for surgery, they received pharmacological treatment for their
comorbidities, thus quantifying waiting list costs. All surgical
procedures were assumed to be performed at a certified center of
excellence, with low complication and mortality rates as sug-
gested by literature [30], and thus not considered in the evalua-
tion. No learning curve for surgeons was assumed, thus
assuming that they yielded the same results in all operations.
In published reports [8,18,31], comorbidity resolution occurs
after surgery; however, each comorbidity is resolved at a different
rate over time [32], while there is a percentage of patients who,
despite not presenting the comorbidity at the time of surgery,
develop it over time. The resolution and re-incidence percentages
of comorbidities were taken from Buchwald et al. [8,18] and the
SOS study [31,33], given that this is the most complete informa-
tion set available for the analyzed arms. For the purposes of the
model, the annual prevalence of each considered comorbidity
was determined by Eqs. 1 and 2:
Prevt¼2
¼Prevt¼0½1Recovery ratet¼2þ Incidence ratet¼2½1Prevt¼0
ð1Þ
Prevt¼10
¼Prevt¼0½1Recovery ratet¼10þ Incidence ratet¼10½1Prevt¼0
ð2Þ
where Prev refers to the prevalence of each comorbidity,
t refers to the year in which the prevalence is estimated, recovery
rate refers to the rate of resolution of the comorbidity, and
incidence rate refers to the rate at which patients develop the
comorbidity during the simulation.
The temporal end points included in the model correspond to
the interpolation of prevalences for years 0.5 and 1 (according to
Fig. 1 – Prevalence of type 2 diabetes.
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study), assuming an exponential growth function. For the control
group, prevalences for years 2 and 10 were derived from the SOS
study, using Eqs. 1 and 2, while for the other years they were
interpolated also by using an exponential growth rate (Figs. 1–3).
For both groups, deterioration of the clinical state was defined as
the possibility of acquiring/developing more than one comorbid-
ity once admitted to the model. Thus, the addition of comorbid-
ities in both groups reflects the deterioration in the patient’s
general health state. Table 2 shows comorbidity-specific preva-
lences resulting from Eqs. 1 and 2 and used during the simulation
for selected time points.
To assess decision uncertainty [34], the model included a
cross-over option: it allowed for 5% of the patients in the
nonsurgical group to undergo bariatric surgery 5 years after
simulation start. In addition, it was assumed that hospital
capacity for carrying out surgeries remained fixed over time. No
revision surgery was considered, and only one surgical procedure
per patient was permitted. Changes in patients’ weight or QOL
associated with the disease or with the compared interventions
were not tracked.
Patients with morbid obesity incur in health care costs
because of the treatment of their comorbidities, which includes
inpatient medical care, outpatient pharmacologic treatment, and
bariatric surgery (for the surgical group only). As there is no local
information on resource utilization, proxies were defined and
used to account for treatment costs. Costs of both hospital care of
comorbidities and bariatric surgery were taken from the 2007Fig. 2 – Prevalence of arMexican Social Security Institute (IMSS) diagnosis-related group
(DRG) list, while the pharmacologic treatment costs for comor-
bidities were taken from published reports by the Mexican
National Institute of Public Health [35]; for hypercholesterolemia,
an identical cost for hypertension was assumed, as there is no
available information (Table 3). Bariatric surgery’s DRG includes
hospital stay and the material used during the procedure.
Given that the model assumes that surgeries take place on a
monthly basis, all costs were assessed per month and adjusted
for inflation as of January 2011 by using official inflation data [36].
Estimated results include the accumulated discounted costs per
considered arm and comorbidity and shown in Mexican pesos
adjusted for inflation as of January 2011. ROI is shown in years
and represents the point of time at which the accumulated costs
of the entire surgical group equal those of the nonsurgical group
(cost breakeven point).
Simulation was programmed to run for 10 years, using an
annual discount rate of 4.5% for costs. Ten repetitions of the
model were performed to generate 95% confidence intervals (CIs).
To evaluate result robustness, a scenario (sensitivity) analysis
was performed by changing the number of monthly surgeries
(25%), the annual discount rate (1.5% on the nominal rate),
and the cost of surgery and treatment of comorbidities (15%
and 30%), in order to reflect modifications on infrastructure, local
economic and risk conditions, and acquisition terms by the
provider.
In addition, the model was run considering a subpopulation of
morbidly obese patients with T2D as their only comorbidity toterial hypertension.
Fig. 3 – Prevalence of hypercholesterolemia.
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patients. For this scenario, recovery rates reported by Buchwald
et al. [8] were used, assuming that T2D resolution was lasting, as
shown by Pories et al. [32], Schauer et al. [37], and Sugerman et al.
[38]. The model was developed by using the Arena software
(Rockwell, Wexford, PA).Results
According to the definition of ROI used in this study, and under
the model’s assumptions, the ROI point for patients with morbid
obesity undergoing bariatric surgery in public health care institu-
tions in Mexico was obtained at 6.8 years (95% CI 6.74–6.86). Total
accumulated discounted costs of the surgical group were 52% less
than conventional treatment group costs in the period of 10 years
projected in the model (Table 4). Bariatric surgery reduced
treatment costs for T2D, AHT, and HCL by 59%, 53%, and 65%,
respectively.
Results of scenario (sensitivity) analysis show that the great-
est effect on ROI was observed when the costs of DRGs associated
with inpatient comorbidity treatment and outpatient pharmaco-
logic treatment were changed, where a reduction of 30% and 15%
in costs increased the ROI time to 9.17 and 7.76 years, respec-
tively. The opposite effect was observed when the same costs
were increased by 30% and 15%, reducing the ROI time to 5.6 and
6.12 years (Table 5). Changing the number of surgical procedures,
discount rates, and total costs (i.e., both DRGs and pharmacologic
treatment of comorbidities, and bariatric surgery’s DRG) had noTable 2 – Comorbidity prevalences used in simulation for
selected years, bariatric surgery and conventional
treatment arms.
Selected years in simulation
0 2 5 10
Bariatric surgery arm (%)
Type 2 diabetes 22.3 5.7 8.3 15.9
Arterial hypertension 41.0 15.7 17.8 21.9
Hypercholesterolemia 27.9 8.0 8.2 8.5
Conventional treatment arm (%)
Type 2 diabetes 22.3 23.8 28.4 38.0
Arterial hypertension 41.0 49.5 55.0 65.4
Hypercholesterolemia 27.9 40.5 41.3 42.6significant effect on ROI (Fig. 4). Costs per patient increased
(decreased) as DRG costs increased (decreased) (Table 6).
For the subgroup of patients with morbid obesity and T2D, the
ROI time for bariatric surgery was 4.44 years (95% CI 4.41–4.47).
Per-patient costs for this subpopulation are lower than base-case
results (Table 7), as T2D was the only considered comorbidity
—that is, preoperative prevalences for AHT and HCL were zero;
thus, no costs for AHT or HCL were considered at any time in the
simulation.Discussion
For this model, and under the considered assumptions, the ROI
point for bariatric surgery was 6.8 years. Resulting output
estimations are different from those reported by other studies,
where ROI results oscillating between 2 and 4 years are found.
Some reasons for this could be that the model incorporates only
the costs resulting from the maintenance treatment of three
comorbidities, unlike other studies that analyze administrative
databases that include the costs of more comorbidities and their
associated complications. The studies by Cre´mieux et al. [23],
Mullen and Marr [24], and Klein et al. [39] are based on the
retrospective analysis of reimbursement requests for drugs and
medical care by patients with morbid obesity undergoing a
bariatric procedure and compared to control cases, while the
present model seeked to carry out a prospective analysis of
bariatric surgery, its development, and consequences. The lim-
itations of database analysis derive mainly from the variables
used for matching patients undergoing surgery and their respec-
tive controls, and from the fact that patients are followed for
a relatively short time after surgery, as discussed by the same
authors.
Another factor that could potentially influence ROI results is
the use of DRGs, which are calculated for general population,
instead of a specific and more detailed microcosting exercise for
morbidly obese patients. It is also possible that the DRGs used to
cost comorbidity treatment underestimate the true cost, particu-
larly by not including complications associated with the comor-
bidity, leading to a different ROI. Information from microcosting
related to the natural history of comorbidities associated with
morbid obesity for the two considered groups is needed.
Assuming correlation between considered comorbidities
could also influence ROI results. While there is local evidence
on the crossed prevalences between comorbidities [40] for the
normal weight and obese population, considering the corre-
sponding correlation values of the former in the model could
Table 3 – Monthly costs associated with the treatment of comorbidities.
Comorbidity/
procedure
DRG
number
DRG monthly
cost ($)
Monthly cost of pharmacological
treatment (outpatient) ($)
Type 2 diabetes 294 2,272 62
Hypertension 134 1,966 47
Hypercholesterolemia 297 2,549 47
Bariatric surgery 288 64,000† NA
DRG, diagnosis-related group; NA, not applicable.
* All costs are expressed in Mexican pesos, adjusted for inflation as of January 2011.
† Surgery is a one-time event, and so the patient incurs its entire cost when having the procedure performed.
Table 4 – Comparison of accumulated discounted costs between bariatric surgery and conventional treatment arms.
Surgical
group ($)
95% CI Nonsurgical group ($) 95% CI
Total cost ($) 19,194,558 19,061,781–19,327,335 39,979,269 39,776,668–40,181,868
Cost per patient ($) 127,963 127,078–128,848 266,527 265,177–267,877
Total cost for type 2 diabetes ($) 3,849,811 3,746,795–3,952,827 9,359,420 9,267,665–9,451,175
Total cost for arterial hypertension ($) 7,291,635 7,162,636–7,420,634 15,422,356 15,296,471–15,548,241
Total cost for hypercholesterolemia ($) 5,219,819 5,067,373–5,372,265] 14,857,782 14,766,678–14,948,886
CI, confidence interval.
* All costs are expressed in Mexican pesos, adjusted for inflation as of January 2011.
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with a BMI of 35 kg/m2 or more is needed to determine the true
economic impact of morbid obesity in the local settings.
There is little information on the incidence and recovery rates
of comorbidities associated with morbid obesity in the long term
(45 years) after bariatric surgery. The small number of clinical
studies with long-term follow-up focus on a limited number
of comorbidities [41,42] and, often, results correspond only to
patients who have undergone surgery, and not to controls [38].
Even more importantly, results are inconsistent, as the targetTable 5 – Results of scenario analysis—ROI (cost break-
even point).
Scenario ROI
(years)
95% CI
Base case 6.8 6.74–6.86
9 surgical procedures/month 6.93 6.85–7.01
15 surgical procedures/month 6.65 6.5–6.8
Discount rate 3% 6.51 6.4–6.58
Discount rate 6% 7.14 7.08–7.2
30% all costs 6.8 6.74–6.86
15% all costs 6.8 6.74–6.86
þ15% all costs 6.8 6.74–6.86
þ30% all costs 6.8 6.74–6.86
30% costs, comorbidity-related DRGs
and pharmacologic treatment
9.17 9.07–9.27
15% costs, comorbidity-related DRGs
and pharmacologic treatment
7.76 7.68–7.84
þ15% costs, comorbidity-related DRGs
and pharmacologic treatment
6.12 6.04–6.2
þ30% costs, comorbidity-related DRGs
and pharmacologic treatment
5.6 5.52–5.68
CI, confidence interval; DRGs, diagnosis-related groups; ROI, return
on investment.population and inclusion characteristics of the study group
conclusively determine the result of the procedure. The studies
by Pories et al. [32], MacDonald et al. [43], and Schauer et al. [37]
consider only patients with preoperative T2D who have under-
gone surgery, resulting in resolution of the comorbidity in almost
83% in the long term (45 years), leading to a low and stable
prevalence over time—a result contrasting with that found in the
SOS study. Thus, studies focusing on subgroups of patients with
morbid obesity, although considered as high risk, do not allow for
an evaluation of the behavior of a cohort that is truly represen-
tative of the morbidly obese population.
Results of the SOS study are based on a 10-year follow-up of
patients with morbid obesity who at the beginning presented
comorbidities such as T2D, AHT, and HCL, both in the interven-
tion group (bariatric surgery) and in the matched controls
[31,33,44]. From the information provided by the SOS study,
it could be deduced that the prevalence of each of the comorbid-
ities is the result of its resolution and incidence at each of the
temporal end points considered in the model. Results reflect the
heterogeneous behavior of comorbidities in this type of patients
at determined points over time, observable both for the de novo
development of comorbidities (given the deterioration of the
patient’s clinical state in both study groups) and for the reappear-
ance of the comorbidity previously resolved by surgery (inter-
vention group only). When the incidence and resolution rates of
comorbidities are translated into annual prevalences for both
study groups by using Eqs. 1 and 2, it is observed that, for T2D
and AHT, there is a rapid resolution effect of bariatric surgery (see
Figs. 1, 2, and 3), with slow incidence and re-incidence of these
comorbidities being observed afterward. The same does not
seem to occur with HCL, which after surgery tends to be resolved
and maintained with minimal re-incidence over the course of
10 years.
Another reason why ROI results shown here are different from
those reported in other publications could be the lack of detailed
information on the long-term resolution of comorbidities classi-
fied according to the surgical procedure undergone by the patient.
It must be established that in its short- and long-term results, the
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Fig. 4 – Results of scenario analysis—return on investment (ROI). DRG, diagnosis-related group.
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undergoing Roux-en-Y gastric bypass, adjustable gastric band,
and vertical gastroplasty with band, with no procedure distinc-
tion in the analysis and report of results. For these reasons, it was
necessary to concentrate the efficacy of bariatric procedures
(resolution of comorbidities) under a single result for each of
the comorbidities evaluated in the model. It is important that
future studies carry out long-term follow-up considering other
comorbidities to enable a more precise clinical and economic
comparison of the procedures and their consequences.Table 6 – Results of scenario analysis—accumulated discounted
Scenario
Base case
9 surgical procedures/month
15 surgical procedures/month
Discount rate 3%
Discount rate 6%
30% all costs
15% all costs
þ15% all costs
þ30% all costs
30% costs, comorbidity-related DRGs and pharmacologic treatment
15% costs, comorbidity-related DRGs and pharmacologic treatment
þ15% costs, comorbidity-related DRGs and pharmacologic treatment
þ30% costs, comorbidity-related DRGs and pharmacologic treatment
CI, confidence interval.
* All costs are expressed in Mexican pesos, adjusted for inflation as of JFinally, resulting cost and ROI estimations appear to be robust
to different sample sizes. While reflecting the current local
conditions for bariatric surgery in the public health system,
simulating the behavior of 150 patients only potentially leads to
stable economic outcomes, as the results for 7,500 patients with
20 repetitions (i.e., considering 150,000 patients as a total target
population) show a cost breakeven point of 6.8 years (95% CI
6.84–6.88) and costs per patient of $127,941 (95% CI $127,829–
$128,053) and $267,355 (95% CI $267,175–$267,535) for the surgical
and nonsurgical arms, respectively. These findings are relevantcosts per patient.
Surgical group Nonsurgical group
Costs ($) 95% CI ($) Costs ($) 95% CI ($)
127,963 127,078–128,858 266,527 265,177–267,877
125,548 124,755–126,341 267,984 267,120–268,848
129,233 128,473–129,993 267,321 266,237–268,405
133,248 132,294–134,202 285,699 284,256–287,142
123,097 122,275–123,919 248,847 247,580–250,114
89,564 88,945–90,183 186,543 185,598–187,488
108,760 108,008–109,512 226,516 225,369–227,663
147,154 146,137–148,171 306,490 304,937–308,043
166,339 165,189–167,489 346,436 344,681–348,191
108,764 108,145–109,383 187,383 186,385–188,381
118,360 117,608–119,112 226,936 225,770–228,102
137,554 136,537–138,571 306,070 304,526–307,614
147,139 145,989–148,289 345,597 343,853–347,341
anuary 2011.
Table 7 – Results for a subpopulation of patients with morbid obesity and type 2 diabetes as the only comorbidity.
Scenario Surgical group Nonsurgical group
Result/costs ($) 95% CI ($) Costs ($) 95% CI ($)
ROI (years) 4.44 4.41–4.47 NA NA
Accumulated discounted costs per patient 109,965 109,512–110,418 228,555 228,054–229,056
Total accumulated discounted costs 16,494,847 16,245,455–16,378,045 34,283,312 34,208,123–34,358,501
CI, confidence interval; NA, not applicable; ROI, return on investment.
* All costs are expressed in Mexican pesos, adjusted for inflation as of January 2011.
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iatric surgery in Mexico.
The results in this study support the findings shown in the
literature on the clinical and economic benefits of bariatric
surgery over conventional treatment for morbidly obese patients.
Considering a long-term follow-up (10 years), overall costs for the
surgical group appear to be less than half of those incurred by the
nonsurgical group. If performed on high-risk subpopulations,
such as patients with T2D, bariatric surgery yields an even
shorter ROI time. Considering the results shown in this study,
and given that Mexico has the second largest obese population
among Organisation for Economic Co-Operation and Develop-
ment countries [45], local health care institutions should consider
implementing strategies to accelerate access of bariatric surgery
as treatment for morbid obesity, as evidence has shown its
effectiveness in other countries.
Source of financial support: These findings are the result of
work supported by Ethicon Endo-Surgery, Inc, Cincinnati, OH.
The views expressed in this article are those of the authors,
and no official endorsement by Ethicon Endo-Surgery, Inc., is
intended or should be inferred.
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